Doctors require more information about cannabis (study result)

Cannapio seedsOur own brandBrowse ›Tip for this articleSpecial Medic CBD - 3pcs Cannapio feminized seeds€9.20Browse ›Tip for this articleAuto Banana OG Kush - autoflowering seeds 5 pcs Cannapio€19.30Browse ›

Recent research highlights a striking paradox in the medical field: while interest in therapeutic cannabis continues to grow among patients, healthcare professionals admit to a critical lack of reliable information about these collectible seeds and their genetic properties.

The gap between patient demand and medical knowledge

Data collected from 237 American oncologists reveals a paradoxical situation: more than half of them have already recommended medical cannabis to their patients, while admitting to having limited knowledge on the subject. This study, published in the Journal of Clinical Oncology, underscores how legislative evolution has outpaced scientific research and medical training.

In 29 US states, physicians can legally prescribe cannabis to oncology patients. However, they struggle to provide solid clinical data to support their recommendations. This gap is explained by the insufficient number of rigorous clinical studies, forcing practitioners to rely on research conducted in other pathological areas.

"We need more quality research and evidence-based clinical data," explains Dr. Ilana Braun of the Boston Institute for Cancer Prevention and Treatment, who led this revealing survey.

The initiative comes mainly from patients

The analysis shows that in 8 out of 10 cases, it is the patients or their loved ones who bring up the topic of therapeutic cannabis during consultations. Conversely, only 1 in 10 physicians spontaneously offers this option to relieve pain or chemotherapy side effects. Even more troubling, among these 10% of proactive practitioners, half admit to not having sufficient information about the properties of different cannabis genetics.

This situation reflects a complex reality: oncologists are not fundamentally opposed to alternative therapeutic approaches. Rather, they express an urgent need for training and access to reliable scientific data regarding cannabinoid profiles and terpene profiles of the various available strains.

The US National Academy of Sciences and Medicine has also stated that "the federal government's blocking of therapeutic cannabis research exposes patients and recreational users to potentially unrecognized risks."

Promising but understudied genetic properties

Despite regulatory obstacles, certain beneficial effects of cannabinoids are now recognized. Approximately 50% of surveyed physicians acknowledge the effectiveness of cannabis against chemotherapy-induced nausea. More significantly, 67% of them consider therapeutic cannabis to be a safer alternative to traditional analgesics and opiates.

Collectible seeds display fascinating genetic profiles, with varying concentrations of THC, CBD, and other minor cannabinoids. These genetic differences determine the aromatic properties and potential therapeutic profiles of each strain, crucial information for understanding their genetic material.

However, some studies raise questions about potential risks, particularly among chronic users: possible increase in traffic accidents, development of bronchitis (when used by combustion), or psychiatric risks in certain vulnerable populations.

Perspectives and official recognition

Dr. Steven Pergam of the Seattle Cancer Care Alliance takes a nuanced approach: "For a terminally ill patient, we must consider anything that can improve their comfort. However, in leukemia patients with weakened immune systems, inhaling cannabis may present infectious risks."

This position illustrates the importance of a personalized approach, taking into account the genetic profile of the strains and the specific clinical condition of each patient.

A complementary survey conducted in Washington state reveals that 74% of citizens are interested in therapeutic cannabis. Paradoxically, access to reliable information remains problematic: only 15% of interested individuals receive advice from healthcare professionals, with the rest turning to informal and often unreliable sources.

Discreet but significant scientific recognition

In 2015, the US National Cancer Institute (NCI), the main government agency for oncology research, discreetly added a remarkable statement to its official publications: "Substances derived from cannabis have successfully destroyed cancer cells in laboratory experiments."

This official recognition is based on preclinical studies demonstrating how certain cannabinoids can block blood supply to tumors and induce cancer cell death in animal models. This research on cannabis genetic material opens fascinating perspectives for understanding the mechanisms of action of the different compounds present in these exceptional collectible seeds.

Although these results remain at the experimental stage, they illustrate the considerable potential contained in the various cannabis genetics and highlight the urgency of developing more ambitious research programs to fully exploit this remarkable genetic heritage.